February 21, 2017
A newly disclosed warning letter to Pfizer is setting off a chain reaction that will likely delay a generic version of Teva's blockbuster Copaxone, one of the world's best-selling drugs. Here's a look at the remarkable development and other U.S. Food and Drug Administration warnings announced in recent days.
January 31, 2017
A Delaware federal judge sided Monday with generic-drug makers including Sandoz, Mylan and Pfizer and invalidated four patents for Teva's multiple sclerosis drug Copaxone they were accused of infringing.